Oct 4, 2022 | Archived
Partnership combines miRecule’s unique RNA therapeutic discovery and conjugation platforms with Sanofi’s NANOBODY® technology to create a groundbreaking treatment for FSHD miRecule will receive an upfront payment with potential future milestone payments of nearly $400...
Sep 30, 2022 | Archived
Read the press release here: SOLVE-FSHD Invests US 1 Million in miRecule to Accelerate Development of Best-in-Class Antibody-RNA-Conjugate to Treat Facioscapulohumeral Muscular...
Feb 28, 2022 | Archived
Gaithersburg, Md., February 28, 2022 – miRecule, Inc. today announces it has won a joint Maryland Industrial Partnerships (MIPS) grant in collaboration with Dr. Robert Bloch at the University of Maryland, Baltimore for $100,000. This collaborative partnership is...
Jun 8, 2021 | Archived
Gaithersburg, MD (June 8, 2021) – miRecule, Inc. (“miRecule”), an emerging biotech company focused on the development of cutting-edge RNA therapeutics, announced the hiring of Fu-An Kang, Ph.D. to serve as its Vice President of Research. Dr. Kang joins miRecule...
May 27, 2021 | Archived
Read the full story here: Global News...
Dec 16, 2020 | Archived
Integrated genomic and functional microRNA analysis identifies miR-30-5p as a tumor suppressor and potential therapeutic nanomedicine in head and neck cancer – Clinical Cancer Research
